Barely Significant
← all excerpts

IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity.

Trials · 2022 · PMC9442941 · PMID 36064434

1
hedged sentence
closest p
boldest claim

The sentences

likely to be significantno p-value reported
placebo for one post-medication time point and one readout variable that are most likely to be significant, based on published literature (see power calculation).

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.